SLS Share Price Performance
US$1.87
0.61 (48.41%)
Price US$1.87
Share PriceUS$1.87
Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?
Jun 25
SELLAS Life Sciences Group, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
SLS Community Narratives
There are no narratives available yet.
SELLAS Life Sciences Group, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.25
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
SELLAS Life Sciences Group, Inc. Competitors
Snowflake Analysis
About SLS
- Founded
- n/a
- Employees
- 15
- CEO
- WebsiteView website
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.2%
- 3 Months: 8.5%
- 1 Year: 17.7%
- Year to Date: 14.8%
Over the last 7 days, the market has risen 1.2%, driven by gains of 2.4% in the Information Technology sector. The market is up 18% over the last 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›